Glimepiride Eg (Glimepiride)

Glimepiride EG is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• Used as monotherapy in patients who cannot achieve glycemic control with lifestyle measures alone.
• Added to other oral antidiabetic agents such as metformin when combination therapy is required.
• May be prescribed when a rapid reduction in blood glucose is desired.
• Considered appropriate for patients with preserved pancreatic beta‑cell function.
• Utilized in clinical practice to simplify dosing regimens due to once‑daily administration.

The safety profile of glimepiride includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Mild to moderate hypoglycemia, especially when meals are missed or delayed.
• Modest weight gain due to increased insulin activity.
• Nausea, abdominal discomfort, or diarrhea.
• Dizziness or headache.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Cutaneous reactions such as rash, Stevens‑Johnson syndrome, or angioedema.
• Hepatotoxicity manifested by elevated liver enzymes or jaundice.

When prescribing Glimepiride EG, clinicians should consider several precautionary factors to minimize risk and ensure appropriate use.

• Assess renal and hepatic function before initiation and periodically during therapy.
• Use caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use in patients with known sulfonylurea hypersensitivity.
• Monitor blood glucose closely during dose adjustments or when starting concomitant medications.
• Educate patients on recognizing and managing hypoglycemia symptoms.
• Consider dose reduction in patients with low body weight or malnutrition.
• Discontinue during pregnancy unless benefits outweigh risks (consult guidelines).

Glimepiride EG can interact with other drugs, affecting its efficacy or safety; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemic effects.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase glimepiride plasma levels.
• MAO‑A inhibitors, which may potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may impair glucose tolerance.
• Corticosteroids, which can increase blood glucose and require dose adjustments.
• Anticoagulants like warfarin, where glimepiride may affect INR stability.